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Abstract. Long noncoding RNAs (lncRNAs) are involved in 
developmental processes and diseases and function as critical 
regulators of a number of different cancer types. Previous 
research has revealed that lncRNAs affect cervical cancer 
development. Steroid receptor activator (SRA), an lncRNA, 
serves as a critical regulator of gynecologic cancer. However, 
the association between SRA expression and cervical cancer 
remains unclear. In the present study, the SRA expression levels 
in patients with cervical cancer were examined and the associa-
tion between SRA expression and clinicopathological factors 
was determined. SRA expression was observed in cervical 
cancer tissues (n=100) and corresponding normal tissues (n=22) 
using reverse transcription-quantitative polymerase chain 
reaction, and its associations with clinical parameters and prog-
nosis were analyzed. SRA expression was significantly greater 
in tissues from patients with cervical cancer compared with in 
control patients (P<0.001). Multivariate analysis revealed that 
high SRA expression was an independent prognostic factor 
of overall survival (hazard ratio=3.714, P=0.031). The present 
study additionally investigated the biofunctional consequences 
of SRA overexpression in vitro using Cell Counting kit-8, 
wound healing migration and Matrigel invasion assays. The 
results demonstrated that SRA overexpression enhanced cell 
proliferation, migration and invasion in vitro. Furthermore, SRA 
overexpression induced the epithelial-mesenchymal transition 
(EMT). Therefore, SRA may promote tumor aggressiveness 
through the upregulation of EMT-associated genes. These 
results indicated that SRA may represent a novel biomarker for 
predicting recurrence and prognosis and serve as a promising 
therapeutic target in cervical cancer.
Introduction
The most common types of malignant tumors in women are breast, 
uterine, cervical, and ovarian cancers. Cervical cancer is one of 
the most common types of cancers and is associated with high 
rates of malignancy-related death in women worldwide. Cervical 
cancer-related morbidity and mortality rates have decreased over 
the last 30 years in many countries due to the widespread use 
of Pap smear screening tests; however, patients with advanced 
stage cervical cancer still have a poor prognosis (1,2). According 
to the GLOBOCAN series reported by the International Agency 
for Research on Cancer, cancers in women have a relatively poor 
prognosis, with a mortality-to-incidence ratio of 32.5% (3). In 
patients with cervical cancer, tumor size, lymph node metastasis, 
and lymph-blood vessel invasion are independent prognostic 
factors for survival. However, due to the heterogeneity of the 
patient population, these factors may not predict prognosis 
accurately (4,5). Therefore, the identification of novel prognostic 
biomarkers is urgently needed to improve the prognosis of 
women with cancer.
Approximately 98% of transcripts in the human genome 
represent RNA that does not encode proteins (6). Although these 
noncoding RNAs (ncRNAs) have previously been considered 
transcriptional noise, there is now evidence that they play impor-
tant roles in most cellular processes, including cell proliferation, 
differentiation, apoptosis, metabolism, and immunity. In addition, 
ncRNAs affect cancer cell phenotypes and gene regulation (7,8). 
In recent years, long ncRNAs (lncRNAs) have also been shown 
to affected DNA binding and the expression of various genes, 
including chromatin modification complex protein‑related activi-
ties. Additionally, lncRNAs regulate gene expression in response 
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to external stimuli or DNA damage. However, the biological 
functions and molecular mechanisms of lncRNAs in human 
diseases and cancers remain largely unknown (9-11).
Steroid receptor activator (SRA), an lncRNA located 
on chromosome 5q31.3, has been shown to activate human 
hormone receptors that are strongly associated with gyneco-
logic cancers, such as ovarian and breast cancers (12,13). SRA 
modulates the functions of a variety of transcription factor 
modulators and can act as a separate scaffold by enhancing the 
transcriptional activity of the steroid receptor in the reporter 
gene. SRA is involved in normal biological processes, such as 
cell death, lipogenesis, steroidogenesis, muscle formation, and 
insulin signaling, and has been shown to have roles in breast 
cancer, prostate cancer, abnormal cardiac development, and 
reduced fertility. Moreover, SRA functionally interacts with 
proteins involved in cleavage and a number of nuclear receptors, 
such as retinoic acid receptors (14). Although SRA is known to 
be related to the progression of malignant tumors, its role in 
cervical cancer has not been elucidated. Previous studies have 
shown that SRA expression in cervical cancer cell lines is asso-
ciated with the progression of malignant tumors (15). However, 
the clinical relevance of SRA expression is still unclear.
Accordingly, in this study, we investigated the expression 
of SRA in cervical cancer cell lines and analyzed the relation-
ships among SRA expression, clinicopathological findings, and 
disease prognosis. Functional analysis was also performed 
to investigate the effects of SRA on cancer cell invasion and 
migration in vitro. Finally, we investigated whether SRA was 
involved in the epithelial-mesenchymal transition (EMT), as a 
major mechanism leading to metastasis, in cervical cell lines.
Patients and methods
Patients and tissue samples. In total, 100 women who under-
went surgery between 2012 and 2017 at Yonsei Severance 
Hospital, Yonsei University (Seoul, Korea) were included in 
this study. Specimens from patients with newly diagnosed inva-
sive stage IA to IVB cervical cancer (International Federation 
of Gynecology and Obstetrics) who had not received prior 
treatment were evaluated. Additionally, 22 normal cervical 
tissues from patients undergoing simple hysterectomy because 
of uterine leiomyomata were obtained as controls. This study 
was approved by the Ethics Committee of Yonsei Severance 
Hospital, and informed consent was obtained from all patients. 
All specimens were immediately frozen in liquid nitrogen and 
stored at ‑80˚C until RNA extraction.
Cell lines and cell culture. The human cervical squamous 
carcinoma SiHa cells was obtained from the Korean Cell Line 
Bank (Seoul, Korea) and provided by the Korea Gynecologic 
Cancer Bank through the Bio and Medical Technology 
Development Program of the Minister of Science, Information 
and Communication Technology and Future Planning, Korea. 
A total of 293 cells were purchased from American Type 
Culture Collection (Manassas, VA, USA). SiHa and 293 cells 
were cultured in Dulbecco's modified Eagle's medium. All 
culture media were supplemented with 10% (v/v) fetal bovine 
serum and 1% penicillin/streptomycin, and cell lines were 
maintained at 37˚C in a humidified atmosphere of 5% CO2 
and 95% air. Culture medium was replaced with fresh medium 
every 2-3 days, and cells that had been passaged less than 
20 times were used in the experiments.
Quantitative real‑time PCR (qRT‑PCR). Total RNA was 
extracted using TRIzol reagent (Invitrogen; Thermo Fisher 
Scientific, Inc., Waltham, MA, USA) according to the manu-
facturer's instructions. One microgram of total RNA was 
reverse transcribed into first-strand cDNA using a reverse 
transcription reagent kit (Bioline, London, UK). The cDNA 
template was amplified by qRT‑PCR using SensiFAST SYBR 
Hi-ROX Mix (Bioline). qRT-PCR was performed on an ABI 
StepOnePlus Real-Time PCR System (Applied Biosystems, 
Foster City, CA, USA). All quantifications were performed 
with U6 as the internal standard. Relative gene expression 
was analyzed using the 2-ΔΔCT method, and the results were 
expressed as extent of change with respect to control values. 
qRT-PCR experiments were replicated at least three times. 
Primers used for PCR are shown in Table I.
Plasmid constructs and generation of stable cell lines. Full-length 
human SRA cDNA was amplified by PCR and inserted into the 
pLenti6/V5-D-TOPO vector using the ViraPower Lentiviral 
Expression System (Invitrogen; Thermo Fisher Scientific, Inc.) 
according to the manufacturer's protocol. The plasmid was trans-
fected into 293FT cells for packaging, and the resulting lentivirus 
was used to infect the desired cell lines. The selection of SRA 
stably transfected cells was performed in medium containing 
blasticidin (Invitrogen; Thermo Fisher Scientific, Inc.).
Cell proliferation assay. Cell proliferation was evaluated using 
Cell Counting kit-8 (CCK-8) assays (Dojindo Laboratories, 
Kumamoto, Japan). Cells were seeded into 6‑well flat‑bottomed 
plates (1x105 cells/well) in 2 ml complete medium. The cells were 
incubated overnight to allow for cell attachment and recovery 
and were subsequently subjected to SRA1 overexpression for 
24, 48, 72, or 96 h. Next, 10 µl CCK-8 solution was added to 
each well, and cells were incubated for 1 h. The absorbance was 
measured at 450 nm using an auto-microplate reader to calculate 
the number of viable cells in each well. The cell survival rate 
was expressed as the absorbance relative to that of the SiHa, 
veoctor cells. Three independent experiments were performed 
in triplicate.
Matrigel invasion assay. Matrigel invasion assays were performed 
using BD Biocoat Matrigel Invasion Chambers (pore size: 8 µm, 
24-well; BD Biosciences, Bedford, MA, USA), according to the 
manufacturer's protocol. Briefly, 1x105 cells were plated in the 
upper chambers in serum-free medium, and complete medium 
was added to the bottom chamber. The chambers were then 
incubated for 48 h at 37˚C in an atmosphere containing 5% CO2. 
Noninvading cells were removed from the upper chambers using 
cotton-tipped swabs. Cells that had invaded through the pores 
into the lower side of the filter were stained (Diff Quik; Sysmes, 
Kobe, Japan), and these cells were then counted using a hemo-
cytometer. Invasion cell was measured using ImageJ software 
(NIH, Bethesda, MD, USA) and the percentage of the invasion 
cell was calculated. Results were standardized to SiHa cells. 
The number of cells that invaded the membrane was counted 
in 10 fields under the x20 objective lens. Original magnifica-
tion, x200. The assay was replicated at least three times.
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Wound healing migration assay. Cell migration was assessed 
using wound healing assays. Briefly, 1x106 cells were seeded 
into 6-well culture plates with serum-containing medium 
and allowed to grow to 90% confluence in complete medium. 
The serum-containing medium was removed, and cells 
were serum starved for 24 h. When the cell density reached 
~100% confluence, an artificial homogenous wound was created 
by scratching the monolayer with a sterile 200-µl pipette tip. 
After scratching, the cells were washed with serum-free medium. 
Images of cells migrating into the wound were captured at 0, 24, 
and 48 h using a microscope. Scratch width was measured using 
NIH ImageJ software, and the percentage of the scratch area 
closed was calculated as (width at 0 h-width at 48 h)/width at 
0 h. Results were standardized to SiHa cells. The migration cells 
was counted in 10 fields under the x20 objective lens. Original 
magnification, x200. The assay was performed in triplicate.
Western blot analysis. Proteins were extracted with RIPA buffer 
(Thermo Fisher Scientific, Inc.). Protein concentrations were 
measured using a Pierce BCA Protein assay kit (Thermo Fisher 
Scientific, Inc.). After boiling with 5X sample buffer, proteins were 
resolved on 10% sodium dodecyl sulfate-polyacrylamide gels 
and transferred electrophoretically to polyvinylidene difluoride 
membranes (Millipore, Billerica, MA, USA). Membranes were 
blocked with 5% nonfat dried milk in 1X Tris-buffered saline 
containing 0.1% Tween-20 (pH 7.6) at room temperature for 
1 h and were then incubated with primary antibodies at 4˚C 
overnight under constant agitation. The primary antibodies 
included rabbit anti-human E-cadherin (1:1,000 dilution), rabbit 
anti-human β-catenin (1:1,000 dilution), and mouse anti-human 
Snail (1:1,000 dilution; all Cell Signaling Technology, Danvers, 
MA, USA). Proteins were visualized using an enhanced 
chemiluminescence system (Amersham, Little Chalfont, UK), 
and band intensities were quantified using a Luminescent Image 
Analyzer (LAS‑4000 mini; Fujifilm, Uppsala, Sweden).
Statistical analysis. The results of the statistical analyses 
(SPSS, version 24.0; IBM, Chicago, IL, USA) were expressed 
as means ± standard deviations (SDs). Pearson's χ2 tests, 
Student's t-tests, and Fisher's exact tests were used to evaluate the 
associations between SRA expression and clinicopathological 
characteristics. To evaluate the performance of the models 
with respect to their discrimination ability, statistics were 
used chi-square values from the logrank test from the receiver 
operating characteristic (ROC) analysis. The median value (1.64) 
was set as the cut‑off value. The groups were classification into 
high and low SRA expression groups at values above and below 
the cut-off value (1.64), respectively. The Kaplan-Meier method 
was used to analyze overall survival times. The log-rank test 
was used to estimate between group differences. Stepwise Cox 
regression model analysis was used for multivariate survival 
analysis of the parameters that were significant in the univariate 
analysis. The statistical tests were two-sided; differences with 
P<0.05 was considered to indicate a statistically significant 
difference.
Results
SRA levels were elevated in patients with cervical cancer 
having poor prognoses. To determine whether SRA expres-
sion in tissues was linked to the clinicopathological features 
of cervical cancer, we evaluated the expression of SRA in 
cervical cancer tissues (n=100) and corresponding normal 
tissues (n=22). SRA expression in cervical cancer tissues 
was more than 3.15-fold that of noncancerous tissues 
Table Ⅰ. Primer sequences used in this study.
 Primer sequence Product
 ----------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------
Gene Forward (5'-3') Reverse (5'-3') Size (base pair)
SRA CTCCCTTCTTACCACCACCA TGCAGATACACAGGGAGCAG 217
U6 CTCGCTTCGGCAGCACA AACGCTTCAGGAATTTGCGT   92
E-cadherin ATTCTGATTCTGCTGCTCTTG AGTAGTCATAGTCCTGGTCCT 421
N-cadherin CCCAAGACAAAGAGACCCAG GCCACTGTGCTTACTGAATTG 140
Snail GAGGCGGTGGCAGACTAG GACACATCGGTCAGACCAG 178
Wnt TGTGAGGTGAAGACCTGCTG AAAGTTGGGGGAGTTCTCGT  207
Vimentin TGGATTCACTCCCTCTGGTT GGTCATCGTGATGCTGAGAA 111
Twist CGGGAGTCCGCAGTCTTA TGAATCTTGCTCAGCTTGTC 150
SRA, steroid receptor activator.
Figure 1. Elevated expression of SRA in cervical cancer tissues. SRA expres-
sion was evaluated in cervical cancer tissues (n=100) and normal tissues 
(n=22) reverse transcription-quantitative polymerase chain reaction with U6 
as an internal control. Data are expressed as the mean ± standard deviation. 
***P<0.0001 vs. normal control. SRA, steroid receptor activator.
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(P=0.00007; Fig. 1). Additionally, we examined the rela-
tionships between SRA expression and clinicopathological 
information in 100 patients with cervical cancer (Table II). 
The mean follow-up period was 60 months. Additionally, 
patients with high SRA expression exhibited higher rates of 
lymphatic invasion and invasive cell type relative to patients 
with low SRA expression; this relationship was statistically 
significant.
The median 5-year survival duration was significantly 
higher in the low SRA expression group than in the high 
SRA expression group (19.7 and 25.1 months, respectively; 
log-rank test: P=0.041; Fig. 2A). The risk model in SRA 
data had an area under curve (AUC) of 0.737 in predicting 
(P=0.001; Fig. 2B). Moreover, Cox univariate proportional 
hazards analysis showed that stage [hazard ratio (HR) =2.809; 
P=0.004], tumor size (HR=2.260; P=0.011), and recurrence 
(HR=2.479; P=0.05) were independent prognostic factors 
for overall survival (Table II). Cox multivariate proportional 
hazards analysis showed that SRA expression (HR=3.714; 
P=0.031), stage (HR=2.809; P=0.004), tumor size (HR=2.143; 
P=0.047), and lymphatic invasion (HR=3.44, P=0.03) were 
independent prognostic factors for overall survival (Table III). 
Both univariate and multivariate proportional hazards analyses 
showed that stage and tumor size were independent prognostic 
factors of overall survival.
Overexpression of SRA increased cell proliferation in cervical 
cancer cells. We previously examined SRA expression levels 
in several cervical cancer cell lines by qRT-PCR (15). Here, 
lentiviral-mediated overexpression of SRA was performed to 
determine the functional role of this lncRNA in SiHa cells. 
SRA-expressing plasmid was prepared using as template a PCR 
product that contained the SRA sequences (Fig. 3A). RT-PCR 
analysis showed that SRA was successfully overexpressed 
in SiHa cells compared with that in control cells (P=0.01; 
Fig. 3B). We next examined the impact of SRA overexpression 
on cell proliferation. The results of CCK-8 assays showed that 
overexpression SRA in SiHa cells increased cell proliferation 
(Fig. 3C), suggesting that SRA was involved in the proliferation 
of cervical cancer cells.
SRA overexpression affected cervical cancer cell migra‑
tion and invasion. Next, the effects of SRA on the invasive 
and migratory behaviors of cells were assessed by Matrigel 
invasion and wound healing assays. Overexpression of SRA 
resulted in increased migration of SiHa cells relative to empty 
vector-expressing controls (P=0.001; Fig. 4A). There was 
a significant difference between the scratch width percent-
ages of each cell line 24 and 48 h after in the SiHa, empty 
vector and SRA overexpression cells (P=0.001; Fig. 4B). 
Furthermore, SRA overexpression in SiHa cells significantly 
increased invasion relative to that in empty vector-expressing 
cells (P=0.001; Fig. 4C). The invasion relative percentages 
of each cell line 48 h after in SiHa, empty vector and SRA 
overexpression groups was significantly different (P=0.001; 
Fig. 4D). The SiHa cells percentages were 100±4.58. The 
empty cell line percentages were 72±13.52. The SRA over-
expression cell line percentages were 173±5.38. Altogether, 
these results indicated that SRA promoted SiHa cell invasion 
and migration in vitro.
Overexpression SRA increased the expression of EMT‑associated 
genes in cervical cancer cells. Because the EMT is important in 
cell migration and invasion, the present study examined whether 
SRA was required for EMT using RT-qPCR and western 
blotting. The overexpression of SRA decreased E-cadherin 
expression and increased N-cadherin, Snail, Wnt5β, Vimentin 
and β-catenin expression (Fig. 5A). Levels of protein in cells 
with overexpressed SRA had decreased E-cadherin expres-
sion and increased N-cadherin, β-catenin, Vimentin, Wnt5β, 
Twist and Snail expression (Fig. 5B). The western blot density 
percentages of each cell line 48 h after in the SiHa, empty vector 
and SRA overexpression cells are presented in Fig. 5C. In addi-
tion, the expression of Snail, a transcription factor that mediates 
the EMT, was upregulated in SRA-overexpressing SiHa 
cells compared with that in cells transfected with the empty 
vector (Fig. 5A-C). These data suggested that upregulation of 
EMT-associated genes could partly explain the involvement of 
SRA in cervical cancer cell migration and invasion.
Discussion
A deeper understanding of the molecular mechanisms under-
lying cervical cancer progression and metastasis is essential 
for the development of more effective therapeutic treatments 
and for identifying new diagnostic markers for cervical cancer. 
lncRNAs are transcripts measuring 200 nucleotides or more 
that do not encode proteins. Although the functional roles of 
small regulatory ncRNAs, such as microRNAs, have been well 
established in human cancers, little is known about the regula-
tory roles of lncRNAs and their relevance to human disease. 
Many lncRNAs are capped, spliced, and polyadenylated with 
protein-coding counterparts (16). lncRNAs have been shown 
to exhibit tissue‑specific expression patterns and have been 
functionally characterized; the biosynthesis of these RNAs 
is important for a variety of physiological processes, and 
abnormal expression of lncRNAs may affect cancer develop-
ment and progression (17). Moreover, lncRNAs are emerging 
as key players in the complex mechanisms underlying malig-
nant processes, including tumorigenesis, drug resistance, and 
metastasis (18-20).
Cervical cancer remains one of the leading causes of 
cancer-related death in women worldwide (21). Despite the 
development of advanced therapeutic strategies, the prognosis 
in patients with cervical cancer varies significantly and is hard 
to predict. Treatment outcomes still depend primarily on early 
detection and diagnosis. Recent studies have demonstrated that 
some abnormal molecular biology changes may play central roles 
in the development of cervical cancer (22). However, there are 
few reports of the biology and function of SRA in cervical cancer 
cells. Accordingly, in this study, investigated the molecular 
function and clinical significance of SRA expression in cervical 
cancer cell lines. We found that SRA expression was higher in 
cervical cancer tissues than in comparable noncancerous tissues. 
Moreover, SRA overexpression altered cell growth, migration, 
and invasion in cervical cancer cells. The metastatic effects of 
SRA appeared to be mediated, at least in part, by the regulation 
of genes involved in cell migration, invasion, and the EMT.
SRA is an lncRNA that acts as a putative coactivator for 
steroid receptor-mediated transcription. Its overexpression and 
consequent deregulated hormone signaling are associated with 
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breast, uterine, ovarian, and prostate cancers (23). Therefore, 
we hypothesized that expression of SRA may affect prognosis 
in patients with cervical cancer. We discovered that SRA 
overexpression increased cervical cancer cell proliferation, 
migration, and invasion. Thus, SRA may be oncogenic in cervical 
cancer and promote aggressive and metastatic characteristics. 
The EMT involves alterations in cell phenotype, and several 
transcription factors have been implicated in the regulation of 
EMT-related gene expression. Although several studies have 
focused on transcriptional regulators in the pathological EMT, 
Table Ⅱ. Clinicopathological features and SRA expression in patients with cervical cancer.
 SRA expression
 -----------------------------------------------------------------------------
Variables n (%) Low High P-valuea
Age (years, mean ± SD) 100 49.425±1.84 51.95±1.61 0.339
Stage    0.094
  Ι, II 64 22 42 
  III, IV 36 18 18 
Lymph node metastasis    0.414
  Yes 35 15 20 
  No 65 25 40 
Lymphatic invasion    0.033
  Yes 37 10 27 
  No 63 30 33 
Tumor size (cm)    0.478
  0-5.9 45 19 29 
  ≥6 53 21 32 
Recurrence    0.515
  Yes 29 12 17 
  No 71 28 43 
Cell type    0.025
  Squamous cell carcinoma 63 20 43 
  Adenocarcinoma 17   9   8 
  Mixed 8   3   5 
  Other 10   7   3 
a Chi-square test or Fisher's exact test were used to calculate P-values. SRA, steroid receptor activator; SD, standard deviation.
Figure 2. (A) Overall survival of patients in the high SRA group demonstrated significantly worse survival rates than those who were in the low SRA group 
(P=0.041). (B) ROC curve for prognosis prediction of patients using SRA level. The AUC is shown in plots. ROC, receiver operating characteristic; AUC, area 
under curve; SRA, steroid receptor activator.
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few studies have evaluated the roles of transcription factors in 
cervical cancer (24).
In this study, high expression of SRA in cervical cancer 
cells induced cell migration and invasion through upregulation 
of EMT-related genes.
Loss of E-cadherin is thought to be an important event 
of EMT, but N-cadherin causes a decrease in intercellular 
junctions between two adjacent endotheliums, which causes 
cancer cells to slip (25). In addition, β-catenin is more mobile 
and weakens the slowly related mesenchymal phenotype. 
Table Ⅲ. Univariate and multivariate analyses of parameters associated with overall survival in 100 patients with cervical cancer.
 Univariate analysis Multivariate analysis
 ------------------------------------------------------------------------------ -----------------------------------------------------------------------------
Factor Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
SRA expression 2.096 (0.747-5.729) 0.162 3.714 (1.128-12.230) 0.031
Age (years) 1.014 (0.976-1.052) 0.483 1.023 (0.983-1.064) 0.27
Stage 2.265 (1.413-3.631) 0.001 2.809 (1.388-5.686) 0.004
Tumor size 2.260 (1.208-4.231) 0.011 2.143 (1.011-4.542) 0.047
Lymph node metastasis 2.252 (0.907-5.588) 0.08 0.751 (0.240-2.350) 0.623
Lymphovascular invasion 1.407 (0.564-3.507) 0.464 3.44 (1.13-10.468) 0.03
Recurrence 2.479 (1.001-6.136) 0.05 2.68 (0.734-9.782) 0.136
Histology 1.185 (0.765-1.837) 0.447 1.434 (0.883-2.330) 0.145
SRA, steroid receptor activator.
Figure 3. SRA promoted cell proliferation in SiHa cells. (A) Map of plasmid pLenti6/V5-D-TOPO and the sequence of the overexpression fusion gene SRA. 
(B) Overexpression of SRA in SiHa cells was analyzed using reverse transcription-quantitative polymerase chain reaction. (C) Cell proliferation was analyzed 
using Cell Counting kit-8 assays. Bars indicate the mean ± standard deviation of three independent experiments. *P<0.05 vs. SiHa, Vector cells. SD, standard 
deviation; SRA, steroid receptor activator.
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The enhancement of the expression of transcription factors 
such as Snail and Twist is associated with the loss of intercel-
lular adhesion (26), vimentin constitutes the main component 
of the cytoskeleton of mesenchymal cells, it's up-regulation 
is induced by EMT (1,27). Recent study have been demon-
strated that HOTAIR regulated the expression of vascular 
endothelial growth factor, matrix metalloproteinase-9 and 
EMT-related genes, which are important for cell motility and 
metastasis (19).
We hypothesized that SRA may act an important regulator 
of several signaling mechanisms associated with the EMT. 
Our results suggested that SRA may contribute to the 
growth, invasion, and recurrence of cervical cancer through 
induction of the EMT. The recurrence rate of radical cervical 
cancer after radical surgery is 15-30%, and the prognosis of 
patients with recurrence is poor (28). A reliable predictor of 
recurrence and progression is needed to improve the prognosis 
of patients with cervical cancer. Cell type in cervical cancer 
is related to patient survival, and squamous cell carcinoma 
has been found to be most closely related to survival (29,30). 
Here, we demonstrated that high SRA expression was related 
to low overall survival rates in patients with squamous 
cell carcinoma. Multi-scale modelling Pelvic lymph node 
metastasis is one of the most important postoperative risk 
factors for relapse or failure to survive. Therefore, patients 
with cervical cancer with metastasis to pelvic lymph nodes 
require adjuvant therapy, such as postoperative radiation 
therapy (31). We also found that high SRA expression was 
related to advanced stage and metastasis. Thus, assessment of 
SRA expression in patients with cervical cancer can inform 
treatment decisions by predicting the risk of progression or 
recurrence.
In summary, we found that patients with cervical cancer 
had elevated SRA levels. Moreover, SRA overexpression was 
positively correlated with clinicopathological parameters 
in cervical cancer, and SRA was found to have a role in 
Figure 4. SRA promoted cell migration and invasion. (A) Wound healing assay observed under the optical microscope were used to determine migration 
in SRA-overexpressing SiHa cells (x200). Cells after 24 and 48 h analyzed and determine for SiHa cells as a control. (B) Presents the wound healing assay 
percentages of each cell line. (C) Cell invasion observed under the optical microscope. Matrigel invasion assays were used to determine invasion after 48 h 
in SRA-overexpressing SiHa cells. (D) Presents the Matrigel invasion assay percentages of each cell line. Each assay was performed in triplicate. Data are 
means ± standard deviation. **P<0.01 vs. SiHa, Vector cells. ***P<0.0001 vs. SiHa, Vector cells. SRA, steroid receptor activator.
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promoting cell growth and invasion through modulation 
of the EMT. These results suggested that SRA may have 
applications in determination of the clinicopathological 
stage and/or prognosis of patients with cervical cancer. 
Accordingly, SRA may be a promising therapeutic target in 
cervical cancer.
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